We’re improving your experience!

Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.

Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.

Stay tuned for these updates, and thank you for being part of our community!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02061761
Title Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications
Therapies
Age Groups: adult
Covered Countries USA | CAN

Facility Status City State Zip Country Details
Local Institution - 0007 Baltimore Maryland 21205 United States Details
Local Institution - 0004 Boston Massachusetts 02215 United States Details
Barbara Ann Karmanos Cancer Institute Detroit Michigan 48201 United States Details
Local Institution - 0010 Saint Louis Missouri 63110 United States Details
Weill Cornell Medical College New York New York 10021 United States Details
Local Institution - 0002 Portland Oregon 97239 United States Details
Local Institution - 0006 Houston Texas 77030 United States Details
Local Institution - 0001 Seattle Washington 98109 United States Details
Local Institution - 0011 Vancouver British Columbia V5Z 4E6 Canada Details
Local Institution - 0012 Toronto Ontario M5G 2M9 Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field